GlassScriptPhysician profile
Emily Tejeda
NPI 1992348684
$3,403.31
in general payments reported to CMS, 2019-2025
27 companies · $1,171 in 2025
The $1,171 reported for 2025 was more than what 89% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $170 · 2022: $348 · 2023: $632 · 2024: $1,082 · 2025: $1,171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,804 · Education: $75.00 · Travel and Lodging: $6.03.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,804.31 |
| Education | $75.00 |
| Travel and Lodging | $6.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $360.04 | 2023-2025 | Tremfya |
| Arcutis Biotherapeutics, INC. | $307.52 | 2024 | Zoryve |
| Amgen INC. | $267.39 | 2023-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $261.71 | 2021-2025 | Nemluvio, Aklief, Twyneo |
| Lilly USA, LLC | $252.17 | 2021-2025 | Ebglyss, Taltz, Olumiant |
| Sun Pharmaceutical Industries INC. | $238.72 | 2022-2025 | Winlevi |
| Incyte Corporation | $206.38 | 2022-2024 | Opzelura |
| Organon LLC | $200.37 | 2025 | Vtama |
| Genzyme Corporation | $198.29 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $147.33 | 2021-2024 | |
| Abbvie INC. | $139.15 | 2021-2025 | |
| Leo Pharma INC. | $132.03 | 2021-2025 | Anzupgo, Adbry |
| Ucb, INC. | $96.61 | 2022-2025 | Bimzelx |
| Dermavant Sciences, INC. | $90.65 | 2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $84.90 | 2024 | Sotyktu |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $83.73 | 2025 | Libtayo |
| Merz North America, INC. | $56.48 | 2022 | |
| Biofrontera INC. | $48.24 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
| Botanix Sb INC | $41.61 | 2025 | Sofdra |
| Radius Health, INC. | $28.57 | 2024 | Tymlos |
| Organogenesis INC. | $28.21 | 2024 | |
| Journey Medical Corporation | $27.32 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.86 | 2025 | Jardiance |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $22.96 | 2025 | Cabtreo, Jublia, Siliq |
| Epi Health, LLC | $22.30 | 2022 | |
| Paratek Pharmaceuticals, INC. | $19.89 | 2025 | Nuzyra |
| Sebela Pharmaceuticals INC. | $13.88 | 2023 | Naftin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Tejeda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.